Portal de Periódicos da CAPES

A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors

2009; Lippincott Williams & Wilkins; Volume: 4; Issue: 2 Linguagem: Inglês

10.1097/coh.0b013e3283223d46

1746-6318

John P. Moore, Daniel R. Kuritzkes,

Immune Cell Function and Interaction

Small molecule inhibitors targeting the CCR5 coreceptor represent a new class of drugs for treating HIV-1 infection. Maraviroc has received regulatory approvals, and vicriviroc is in phase 3 trials. Understanding how resistance to these drugs develops and is diagnosed is essential to guide clinical practice. We review what has been learned from in-vitro resistance studies, and how this relates to what is being seen, or can be anticipated, in clinical studies.